Early trial tests novel drug combo for tough blood cancers

NCT ID NCT05275439

Summary

This early-stage study aimed to test the safety and initial effectiveness of a new drug called SL-172154. It was given alone or combined with standard drugs (azacitidine and/or venetoclax) to adults with higher-risk forms of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). The main goal was to find a safe dose and see how the body processes the drug, while also checking for early signs that it might help control the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Baylor Scott & White Research Institute

    Dallas, Texas, 75246, United States

  • City of Hope

    Duarte, California, 91010, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Imperial College Healthcare NHS Trust

    London, W12 0HS, United Kingdom

  • Jewish General Hospital

    Montreal, Quebec, H3T 1E2, Canada

  • King's College Hospital NHS Foundation Trust

    London, Denmark Hill, SE5 9RS, United Kingdom

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • Norton Cancer Institute

    Louisville, Kentucky, 40202, United States

  • Princess Margaret Cancer Centre

    Toronto, Ontario, M5G 2C1, Canada

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York, 14263, United States

  • START Midwest

    Grand Rapids, Michigan, 49546, United States

  • The Christie NHS Foundation Trust

    Manchester, M20 4BX, United Kingdom

  • The University of Chicago

    Chicago, Illinois, 60637, United States

  • Tom Baker Cancer Centre

    Calgary, Alberta, T2N 4N2, Canada

  • UCLA Medical Center-Bowyer Oncology Center

    Los Angeles, California, 90095, United States

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania, 15232, United States

  • University Hospitals Plymouth NHS Trust, Derriford Hospital

    Crownhill, Plymouth, PL6 8DH, United Kingdom

  • University of Cincinnati Medical Center

    Cincinnati, Ohio, 45219, United States

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

  • University of North Carolina, Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina, 27599, United States

  • VCU Massey Cancer Center

    Richmond, Virginia, 23219, United States

  • Yale Cancer Center

    New Haven, Connecticut, 06510, United States

Conditions

Explore the condition pages connected to this study.